Research and Markets Adds Nanotechnology for Drug Discovery and Drug Design to Their offering
News Mar 27, 2006
Research and Markets has announced the addition of Nanotechnology for Drug Discovery and Drug Design to their offering.
Nanotechnology has uses in many fields besides biomedical science. Governments have recognized the broad reach of nanotechnology, and they have poured large sums of money into nanotech R&D to ensure their future competitiveness.
This investment has already yielded many discoveries in the field, and it is broadening opportunities for nanotechnology in drug discovery and research.
In this report, Decision Resources describe various nanotechnologies under development for biological and medical purposes and assess their potential. Also highlight the activities of companies applying nanotechnology to the biological and medical sciences.
Business Implications: Nanotechnology is an emerging science that could have far-reaching and paradigm-shifting implications for biology, drug discovery, and medical technologies.
Nanotechnologies for biological applications already in use include liposomal drug-delivery agents, transfection agents, and magnetic resonance imaging contrast agents.
An important advantage of nanotechnology will be its ability to enable and improve upon other technologies, including RNA interference, gene delivery, and proteomics.
Multifunctional nanoparticles that combine targeting, delivery, and imaging components will have important clinical potential but a complex regulatory path.
The first and most extensive use of multifunctional nanoparticles will be applications in the area of drug target and lead validation studies.
These multifunctional particles and complex combination technologies will carry very complex intellectual property issues that will likely lead to the need for multiparty licensing.
Many governments have recognized the importance of harnessing nanotechnology to achieve industrial competitiveness and have invested heavily in funding nanotechnology research and innovation.
In the absence of private and venture investment, various government initiatives have fostered the growth of numerous nanotechnology companies.
These companies have a variety of business models, and many are focused on research tool development, in vivo imaging, and drug delivery.
Nanotechnology drug-delivery companies seeking to partner with pharmaceutical companies face competition from a plethora of available drug-delivery systems.
Nevertheless, pharmaceutical companies may choose to develop their own systems using skills gleaned from corporate partnerships; this approach may be an advantage to nanotechnology companies.
The report anticipates that pharmaceutical companies will continue to partner with a variety of nanotechnology companies to find the best technologies for drug-delivery and discovery needs.
Contents Include: Introduction, Nanotechnology and Nanoparticles, Nanotechnology in Biology and Biomedicine, Nanotechnologies and Applications, Government Initiatives, Hurdles and Challenges to Implementation, Business Models and Strategies, Company Profiles, Outlook for Nanotechnology in Drug Discovery and Design.
Companies Mentioned: Advanced Magnetics, Alnis BioSciences, Alza (subsidiary of Johnson & Johnson), BioDelivery Sciences International, C Sixty, Calando Pharmaceuticals, Dendritic NanoTechnologies, Hermes Biosciences, ImaRx Therapeutics, iMEDD, Intradigm, Kereos, MagForce Nanotechnologies, MolecularDiamond Technologies, NanoCarrier, Nanoprobes, Nanospectra Biosciences, Nanosphere, NanoString Technologies, Protiva Biotherapeutics, Qiagen, Quantum Dot, Starpharma and Triton BioSystems.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.